ARTICLE | Clinical News

Motif Bio preclinical data

September 7, 2015 7:00 AM UTC

In vitro, the minimum inhibitory concentration of iclaprim with antimicrobial activity against 50% (MIC50) and 90% (MIC90) of isolates was 0.06 and 0.12 ug/mL, respectively. The broad-spectrum antibiotic that inhibits dihydrofolate reductase (DHFR) was tested against >2,000 bacterial strains, including 1,178 strains of Staphylococcus aureus. Iclaprim had MIC50 and MIC90 concentrations of 0.06 and 0.5 ug/mL against methicillin-resistant S. aureus (MRSA). Iclparim has Qualified Infectious Disease Product (QIDP) designation in the U.S. to treat hospital-acquired bacterial pneumonia (HABP) and acute bacterial skin and skin structure infections (ABSSSIs). Motif said has not yet determined a development timeline in HABP but this half, the company plans to start Phase III trials of iclaprim to treat ABSSSIs. ...